WuXi agrees to Charles River's $1.6 billion bid

The Shanghai provider of outsourced drug-research services agrees to be acquired for $21.25 a share, or $1.6 billion, of cash and stock by Charles River Laboratories.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.